<SEC-DOCUMENT>0000784199-19-000151.txt : 20190911
<SEC-HEADER>0000784199-19-000151.hdr.sgml : 20190911
<ACCEPTANCE-DATETIME>20190911161220
ACCESSION NUMBER:		0000784199-19-000151
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20190911
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190911
DATE AS OF CHANGE:		20190911

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRYOLIFE INC
		CENTRAL INDEX KEY:			0000784199
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				592417093
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13165
		FILM NUMBER:		191088441

	BUSINESS ADDRESS:	
		STREET 1:		1655 ROBERTS BOULEVARD N W
		CITY:			KENNESAW
		STATE:			GA
		ZIP:			30144
		BUSINESS PHONE:		7704193355

	MAIL ADDRESS:	
		STREET 1:		1655 ROBERTS BOULEVARD N W
		CITY:			KENNESAW
		STATE:			GA
		ZIP:			30144
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cry-20190911x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Inline XBRL document created by Certent Disclosure Management 1.0.0.0-->
<!--Created on: 09/11/2019 20:07:36 PM-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:cry="http://www.cryolife.com/20190911" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <head>
    <title>cry-20190911x8k</title>
    <meta http-equiv="Content-Type" content="text/html" /></head>
  <body xml:lang="en-US">
    <div style="display:none"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="ct-nonNumeric-1" contextRef="Duration_9_11_2019_To_9_11_2019" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="ct-nonNumeric-9" contextRef="Duration_9_11_2019_To_9_11_2019">0000784199</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cry-20190911.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_9_11_2019_To_9_11_2019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-11</xbrli:startDate><xbrli:endDate>2019-09-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
    <div></div>
    <div><div style="border-top: none; border-bottom: 2.5pt double rgb(0, 0, 0); padding-bottom: 1pt; border-right: none; border-left: none"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 6pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 6pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></div><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 6pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 6pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 14pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 14pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">UNITED STATES</span></p><p dir="ltr" style="margin: 0 0 8pt; text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 14pt; line-height: 108%"><span id="_DV_M1" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 14pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">SECURITIES AND EXCHANGE COMMISSION</span><span style="white-space: pre-wrap; font-size: 14pt; font-style: normal; font-weight: bold; margin: 0; padding: 0"><br />&#8206;</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-variant: small-caps; font-style: normal; font-weight: bold; margin: 0; padding: 0">Washington, D.C. 20549</span><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0"><br />&#8206;</span><span id="_DV_M2" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 8pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">___________________________________________</span></p><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 14pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 14pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">FORM </span><ix:nonNumeric name="dei:DocumentType" id="ct-nonNumeric-4" contextRef="Duration_9_11_2019_To_9_11_2019"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 14pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">8-K</span></ix:nonNumeric></p><p dir="ltr" style="margin: 0 0 8pt; text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 8pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 8pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">___________________________________________</span></p><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">CURRENT REPORT</span><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0"><br />&#8206;</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">PURSUANT TO SECTION 13 OR 15(d) OF THE</span></p><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span id="_DV_M3" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">SECURITIES EXCHANGE ACT OF 1934</span><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0"><br />&#8206;</span></p><p dir="ltr" style="margin: 0 0 8pt; text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Date of Report (Date of earliest event reported): </span><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="ct-nonNumeric-3" contextRef="Duration_9_11_2019_To_9_11_2019" format="ixt:datemonthdayyearen"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">September 11, 2019</span></ix:nonNumeric><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0"><br />&#8206;</span><span id="_DV_M5" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 8pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">___________________________________________</span></p><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 14pt; line-height: 108%; margin: 0 0 0.001pt"><span id="_DV_M6" style="text-decoration: none"></span><ix:nonNumeric name="dei:EntityRegistrantName" id="ct-nonNumeric-13" contextRef="Duration_9_11_2019_To_9_11_2019"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 14pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">CRYOLIFE, INC.</span></ix:nonNumeric></p><p dir="ltr" style="margin: 0 0 8pt; text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span id="_DV_M7" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">(Exact name of registrant as specified in its charter)</span><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0"><br />&#8206;</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 8pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">___________________________________________</span></p><div style="text-align:left; "><table dir="ltr" style="border-collapse: collapse; border: none; width: 100%; margin-left: 0; margin-right: auto; margin-bottom: 0.001pt"><tr style="height: 0.01in"><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span id="_DV_M8" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td></tr><tr><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td></tr><tr><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="ct-nonNumeric-12" contextRef="Duration_9_11_2019_To_9_11_2019" format="ixt-sec:stateprovnameen"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Florida</span></ix:nonNumeric></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><ix:nonNumeric name="dei:EntityFileNumber" id="ct-nonNumeric-11" contextRef="Duration_9_11_2019_To_9_11_2019"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">1-13165</span></ix:nonNumeric></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="ct-nonNumeric-14" contextRef="Duration_9_11_2019_To_9_11_2019"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">59-2417093</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">(State or Other Jurisdiction</span><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"><br />&#8206;</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">of Incorporation)</span></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">(Commission File Number)</span></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">(IRS Employer</span></p><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">Identification No.)</span></p></td></tr></table></div><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="ct-nonNumeric-5" contextRef="Duration_9_11_2019_To_9_11_2019"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">1655 Roberts Boulevard, N.W.</span></ix:nonNumeric><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">, </span><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="ct-nonNumeric-6" contextRef="Duration_9_11_2019_To_9_11_2019"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Kennesaw</span></ix:nonNumeric><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">, </span><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="ct-nonNumeric-8" contextRef="Duration_9_11_2019_To_9_11_2019" format="ixt-sec:stateprovnameen"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Georgia</span></ix:nonNumeric><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">  </span><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="ct-nonNumeric-7" contextRef="Duration_9_11_2019_To_9_11_2019"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">30144</span></ix:nonNumeric><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"><br />&#8206;</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 8pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">(Address of principal executive office) (zip code)</span><span style="white-space: pre-wrap; font-size: 8pt; font-style: normal; font-weight: bold; margin: 0; padding: 0"><br />&#8206;</span></p><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span id="_DV_M9" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Registrant&apos;s telephone number, including area code: (</span><ix:nonNumeric name="dei:CityAreaCode" id="ct-nonNumeric-2" contextRef="Duration_9_11_2019_To_9_11_2019"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">770</span></ix:nonNumeric><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">) </span><ix:nonNumeric name="dei:LocalPhoneNumber" id="ct-nonNumeric-15" contextRef="Duration_9_11_2019_To_9_11_2019"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">419-3355</span></ix:nonNumeric><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0"><br />&#8206;</span></p><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span id="_DV_M10" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">_________________________________________________________</span><span id="_DV_M11" style="text-decoration: none"></span></p><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 8pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 8pt; font-style: normal; font-weight: bold; margin: 0; padding: 0"> (Former name or former address, if changed since last report)</span></p><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span id="_DV_M12" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><div style="text-align:center; "><table dir="ltr" style="border-collapse: collapse; border: none; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0.001pt"><tr style="height: 0.01in"><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span id="_DV_M13" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td></tr><tr><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td></tr><tr><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Title of each class</span></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Trading Symbol(s)</span></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Name of each exchange </span><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0"><br />&#8206;</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">on which registered</span></p></td></tr><tr><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><ix:nonNumeric name="dei:Security12bTitle" id="ct-nonNumeric-18" contextRef="Duration_9_11_2019_To_9_11_2019"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">Common Stock, $0.01 par value</span></ix:nonNumeric></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><ix:nonNumeric name="dei:TradingSymbol" id="ct-nonNumeric-21" contextRef="Duration_9_11_2019_To_9_11_2019"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">CRY</span></ix:nonNumeric></p></td><td style="vertical-align: top; width: 33.3%; border-style: none; padding: 0"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><ix:nonNumeric name="dei:SecurityExchangeName" id="ct-nonNumeric-19" contextRef="Duration_9_11_2019_To_9_11_2019"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">NYSE</span></ix:nonNumeric></p></td></tr></table></div><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="margin: 0 0 8pt; text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 8pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 8pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">___________________________________________</span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></p><p dir="ltr" style="text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="margin: 0 0 0.001pt 0.25in; text-indent: -0.25in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><ix:nonNumeric name="dei:WrittenCommunications" id="ct-nonNumeric-22" contextRef="Duration_9_11_2019_To_9_11_2019" format="ixt:booleanfalse"><span style="white-space: pre-wrap; font-family: Wingdings; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0"><span style="font-family: &quot;Wingdings&quot;; white-space: pre-wrap">o</span></span><span id="_DV_M14" style="text-decoration: none"></span></ix:nonNumeric><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0">&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p dir="ltr" style="margin: 0 0 0.001pt 0.25in; text-indent: -0.25in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="margin: 0 0 0.001pt 0.25in; text-indent: -0.25in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span id="_DV_M15" style="text-decoration: none"></span><ix:nonNumeric name="dei:SolicitingMaterial" id="ct-nonNumeric-20" contextRef="Duration_9_11_2019_To_9_11_2019" format="ixt:booleanfalse"><span style="white-space: pre-wrap; font-family: Wingdings; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0"><span style="font-family: &quot;Wingdings&quot;; white-space: pre-wrap">o</span></span></ix:nonNumeric><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0">&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p dir="ltr" style="margin: 0 0 0.001pt 0.25in; text-indent: -0.25in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="margin: 0 0 6pt 0.25in; text-indent: -0.25in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span id="_DV_M16" style="text-decoration: none"></span><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="ct-nonNumeric-17" contextRef="Duration_9_11_2019_To_9_11_2019" format="ixt:booleanfalse"><span style="white-space: pre-wrap; font-family: Wingdings; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0"><span style="font-family: &quot;Wingdings&quot;; white-space: pre-wrap">&#168;</span></span></ix:nonNumeric><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0">&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p dir="ltr" style="margin: 0 0 0.001pt 0.25in; text-indent: -0.25in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="ct-nonNumeric-16" contextRef="Duration_9_11_2019_To_9_11_2019" format="ixt:booleanfalse"><span style="white-space: pre-wrap; font-family: Wingdings; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0"><span style="font-family: &quot;Wingdings&quot;; white-space: pre-wrap">o</span></span><span id="_DV_M17" style="text-decoration: none"></span></ix:nonNumeric><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0">&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span id="_DV_M18" style="text-decoration: none"></span></p><p dir="ltr" style="margin: 12pt 0 6pt; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></p><p dir="ltr" style="margin: 12pt 0 6pt; text-align: justify; font-family: &quot;Arial&quot;, &quot;sans-serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">Emerging growth company </span><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="ct-nonNumeric-10" contextRef="Duration_9_11_2019_To_9_11_2019" format="ixt:booleanfalse"><span style="white-space: pre-wrap; color: rgb(0, 0, 0); font-family: Wingdings; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"><span style="font-family: &quot;Wingdings&quot;; white-space: pre-wrap">&#168;</span></span></ix:nonNumeric></p><p dir="ltr" style="margin: 0 0 6pt; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span><span style="white-space: pre-wrap; color: rgb(0, 0, 0); font-family: Wingdings; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"><span style="font-family: &quot;Wingdings&quot;; white-space: pre-wrap">&#168;</span></span></p><div style="border-top: none; border-bottom: 2.5pt double rgb(0, 0, 0); padding-bottom: 1pt; border-right: none; border-left: none"><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 6pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 6pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></div><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 6pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 6pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0"><br />&#8206;</span><span style="white-space: pre-wrap; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></div>
    <div><div></div><hr style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div><p dir="ltr" style="text-align: right; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap"> </span></p><p dir="ltr" style="text-align: right; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="margin: 0 0 0.001pt 0.25in; text-indent: -0.25in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-size: 11pt; letter-spacing: 0; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><div style="text-align:left; "><table dir="ltr" style="border-collapse: collapse; border: none; width: 100%; margin-left: 0; margin-right: auto; margin-bottom: 0.001pt"><tr style="height: 0.01in"><td style="vertical-align: top; width: 16.2%; border-style: none; padding: 0; background: rgb(255, 255, 255)"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 83.8%; border-style: none; padding: 0; background: rgb(255, 255, 255)"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td></tr><tr><td style="vertical-align: top; width: 16.2%; border: none; background: rgb(255, 255, 255); padding-top: 0; padding-bottom: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Item 1.01.</span></p></td><td style="vertical-align: top; width: 83.8%; border: none; background: rgb(255, 255, 255); padding-top: 0; padding-bottom: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Entry into a Material Definitive Agreement.</span></p></td></tr></table></div><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: italic; font-weight: bold; margin: 0; padding: 0">Exclusive Distribution Agreement </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span id="_DV_M19" style="text-decoration: none"></span><span id="_DV_M20" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">On September 11, 2019, CryoLife, Inc.&#8217;s wholly owned subsidiary, JOTEC GmbH, or JOTEC, entered into an Exclusive Distribution Agreement with an Israeli corporation named Endospan Ltd., or Endospan, pursuant to which JOTEC obtained exclusive distribution rights with respect to Endospan&#8217;s Nexus&#8482; stent graft system and accessories in certain countries in Europe in exchange for a fixed distribution fee in the amount of $9 million.  CryoLife Inc., or Cryolife, also entered into a Securities Purchase Option Agreement with Endospan, providing CryoLife the option to purchase all of the outstanding securities of Endospan from Endopsan&#8217;s existing securityholders, or the option to acquire all of Endospan&#8217;s assets, with such option expiring 90 days after receiving notice that Endospan has received approval from the U.S. Food and Drug Administration, or the FDA, for its Nexus&#8482; product.  </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">Under the terms of the Exclusive Distribution Agreement, JOTEC agreed to use its best efforts to market, promote, distribute, sell and support the Nexus&#8482; products for approved uses in the territories subject to JOTEC&#8217;s exclusive distribution rights.  JOTEC is obligated to satisfy a minimum purchase amount of EUR 900,000 in 2020, with purchases in 2019 counting toward this minimum purchase amount for 2020.  Additional product purchases under the Exclusive Distribution Agreement will be subject to non-binding quarterly rolling forecasts.</span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">The term of JOTEC&#8217;s exclusive distribution rights expires upon the earliest to occur of (i) the date on which the acquisition contemplated by the Securities Purchase Option Agreement can no longer be consummated under its terms, or (ii) the date on which such Securities Purchase Option Agreement is terminated pursuant to its terms, subject to earlier termination by either party under certain circumstances.  JOTEC would be entitled to a termination fee in the event the Exclusive Distribution Agreement is terminated by JOTEC due to a suspension of approvals related to the Nexus&#8482; product lasting more than 6 months or the withdrawal of such approvals, or a temporary injunction on the Nexus&#8482; product lasting 6 months or more or a permanent injunction on the Nexus&#8482; product (unless such injunction resulted solely from an act or omission of JOTEC, its affiliates, or their sub-distributors).  </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">The foregoing description of the Exclusive Distribution Agreement does not purport to be complete and is qualified in its entirety by reference to the Exclusive Distribution Agreement, a copy of which is to be filed with CryoLife&#8217;s Quarterly Report on Form 10-Q for the quarter ending September 30, 2019. </span></p><p dir="ltr" style="text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: italic; font-weight: bold; margin: 0; padding: 0">Loan Agreement &amp; Debenture</span></p><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">&#160;</span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">CryoLife and Endospan also entered into a Loan Agreement, dated as of September 11, 2019, pursuant to which CryoLife agreed to provide Endospan a secured loan in an amount of up to $15 million, with the loan to be funded in three tranches in the amount of $5 million each.  </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">The first tranche of this loan is to be funded within 14 business days of the date of the Loan Agreement, the second tranche is to be funded within 14 business days of Endospan notifying CryoLife that the Nexus</span><span id="_Hlk18648725" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">&#8482;</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> product received Investigational Device Exemption, or IDE, approval from the FDA, and providing a copy of such IDE approval to CryoLife, and the third tranche is to be funded within 14 business days after the enrolment of at least 50% of the required number of patients in the primary arm of the FDA approved clinical trial for the Nexus&#8482; product, in each case subject to Endospan&#8217;s continued compliance with the Loan Agreement and certain other conditions.  If a termination fee becomes payable by Endospan under the Exclusive Distribution Agreement, it will be added to the amount payable under the Loan Agreement.</span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">The loan is secured pursuant to a Debenture entered into between CryoLife and Endospan dated September 11, 2019, which grants CryoLife a security interest over substantially all of Endospan&#8217;s assets.  Such security interest is a first priority security interest, except as to a pre-existing security interest granted to a third party. </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></div>
    <div><div><p dir="ltr" style="line-height: 10pt; text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap">-</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap">2</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap">-</span></p></div><hr style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div><p dir="ltr" style="text-align: right; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap"> </span></p><p dir="ltr" style="text-align: right; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">The loan bears interest at a rate of 5% per annum and is subject to acceleration upon an event of default.  Interest on the loan is payable upon the closing of the acquisition contemplated in the Securities Purchase Option Agreement, and the principal amount and any additional interest or other obligations are payable upon the first anniversary of the closing of such acquisition.  </span></p><p dir="ltr" style="text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">&#160;</span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">The foregoing description of the Loan Agreement and Debenture does not purport to be complete and is qualified in its entirety by reference to the Loan Agreement and Debenture, copies of which are to be filed with CryoLife&#8217;s Quarterly Report on Form 10-Q for the quarter ending September 30, 2019.</span></p><p dir="ltr" style="text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">References to Nexus&#8482; refer to Endospan&#8217;s Nexus&#8482; product.  All brands, product names, company names, trademarks and service marks are the properties of their respective owners.</span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><div style="text-align:left; padding-left: 0"><table dir="ltr" style="border-collapse: collapse; border: none; width: 100%; margin-left: 0; margin-right: auto; margin-bottom: 0.001pt"><tr style="height: 0.01in"><td style="vertical-align: top; width: 16.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 83.7%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td></tr><tr><td style="vertical-align: top; width: 16.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Item 7.01</span></p></td><td style="vertical-align: top; width: 83.7%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Regulation FD Disclosure</span></p></td></tr></table></div><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">On September 11, 2019, the Company issued a press release announcing the execution of the Exclusive Distribution Agreement, a copy of which is furnished as Exhibit 99.1 hereto and incorporated herein by reference. </span></p><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to Item 7.01 of this Current Report on Form 8-K.</span></p><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><div style="text-align:left; padding-left: 0"><table dir="ltr" style="border-collapse: collapse; border: none; width: 100%; margin-left: 0; margin-right: auto; margin-bottom: 0.001pt"><tr style="height: 0.01in"><td style="vertical-align: top; width: 16.2%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 83.8%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td></tr><tr><td style="vertical-align: top; width: 16.2%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Item 9.01</span></p></td><td style="vertical-align: top; width: 83.8%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">Financial Statements and Exhibits</span></p></td></tr></table></div><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">(d)&#160;&#160;&#160;&#160;</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">Exhibits</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">.</span></p><p dir="ltr" style="text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><div style="text-align:left; "><table dir="ltr" style="border-collapse: collapse; border: none; width: 100%; margin-left: 0; margin-right: auto; margin-bottom: 0.001pt"><tr style="height: 0.01in"><td style="vertical-align: top; width: 16.3%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 83.7%; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td></tr><tr><td style="vertical-align: top; width: 16.3%; border: none; padding-top: 0; padding-bottom: 0"><p dir="ltr" style="text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; text-decoration: underline; font-style: normal; font-weight: bold; margin: 0; padding: 0">Exhibit No.</span></p></td><td style="vertical-align: top; width: 83.7%; border: none; padding-top: 0; padding-bottom: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; text-decoration: underline; font-style: normal; font-weight: bold; margin: 0; padding: 0">Description</span></p></td></tr><tr><td style="vertical-align: top; width: 16.3%; border: none; padding-top: 0; padding-bottom: 0"><p dir="ltr" style="text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">99.1</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">**</span></p></td><td style="vertical-align: top; width: 83.7%; border: none; padding-top: 0; padding-bottom: 0"><p dir="ltr" style="text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><a href="cry-20190911xex99_1.htm"><span style="white-space: pre-wrap; color: rgb(0, 0, 255); font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; text-decoration: underline; font-style: normal; font-weight: normal; margin: 0; padding: 0">Press Release of CryoLife, Inc., dated September 11, 2019</span></a></p></td></tr><tr><td colspan="2" style="vertical-align: top; width: 100%; border: none; padding-top: 0; padding-bottom: 0"><p dir="ltr" style="text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">** Furnished herewith, not filed.</span></p></td></tr></table></div><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"><br />&#8206;</span><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></div>
    <div><div><p dir="ltr" style="line-height: 10pt; text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap">-</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap">3</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap">-</span></p></div><hr style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div><p dir="ltr" style="text-align: right; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap"> </span></p><p dir="ltr" style="text-align: right; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap"> </span></p></div></div>
    <div><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: bold; margin: 0; padding: 0">SIGNATURES</span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span id="_DV_M39" style="text-decoration: none"></span><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><p dir="ltr" style="text-indent: 0.5in; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p><div style="text-align:left; padding-left: 0"><table dir="ltr" style="border-collapse: collapse; border: none; width: 100%; margin-left: 0; margin-right: auto; margin-bottom: 0.001pt"><tr style="height: 0.01in"><td style="vertical-align: top; width: 216pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 36pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 244.8pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td></tr><tr><td style="vertical-align: top; width: 216pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 36pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 244.8pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 1pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 1pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td></tr><tr><td style="vertical-align: top; width: 216pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td colspan="2" style="vertical-align: top; width: 36pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">CRYOLIFE, INC.</span></p></td></tr><tr><td style="vertical-align: top; width: 216pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 36pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">&#160;</span></p></td><td style="vertical-align: top; width: 244.8pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td></tr><tr><td style="vertical-align: top; width: 216pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 36pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 244.8pt; border-style: none; padding: 0"><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td></tr><tr><td style="vertical-align: top; width: 216pt; border-style: none; padding: 0"><p dir="ltr" style="margin: 0 0 0.001pt; text-indent: 0; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">Date:  September 11, 2019</span></p></td><td style="vertical-align: top; width: 36pt; border-style: none; padding: 0"><p dir="ltr" style="margin: 0 0 0.001pt; text-indent: 0; text-align: left; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">By:</span></p></td><td style="vertical-align: top; width: 244.8pt; border-style: none none solid; padding: 0; border-bottom-width: 1pt; border-bottom-color: rgb(0, 0, 0)"><p dir="ltr" style="margin: 0 0 0.001pt; text-indent: 0; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">/s/ Jean F. Holloway</span></p></td></tr><tr><td style="vertical-align: top; width: 216pt; border-style: none; padding: 0"><p dir="ltr" style="margin: 0 0 0.001pt; text-indent: 0; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 36pt; border-style: none; padding: 0"><p dir="ltr" style="margin: 0 0 0.001pt; text-indent: 0; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">Name:</span></p></td><td style="vertical-align: top; width: 244.8pt; border-top: 1pt solid rgb(0, 0, 0); padding: 0; border-right-style: none; border-bottom-style: none; border-left-style: none"><p dir="ltr" style="margin: 0 0 0.001pt; text-indent: 0; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">Jean F. Holloway</span></p></td></tr><tr><td style="vertical-align: top; width: 216pt; border-style: none; padding: 0"><p dir="ltr" style="margin: 0 0 0.001pt; text-indent: 0; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></td><td style="vertical-align: top; width: 36pt; border-style: none; padding: 0"><p dir="ltr" style="margin: 0 0 0.001pt; text-indent: 0; text-align: justify; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">Title:</span></p></td><td style="vertical-align: top; width: 244.8pt; border-style: none; padding: 0"><p dir="ltr" style="margin: 0 0 0.001pt; text-indent: 0; text-align: left; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; line-height: 108%"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0">Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary</span></p></td></tr></table></div><p dir="ltr" style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 12pt; line-height: 108%; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0"> </span></p></div>
    <div><p dir="ltr" style="line-height: 10pt; text-align: center; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; margin: 0 0 0.001pt"><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap">-</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap">4</span><span style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 11pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; white-space: pre-wrap">-</span></p></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cry-20190911xex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.32.0.1-->
<!--Created on: 9/11/2019 4:07:54 PM-->
<html>
	<head>
		<title>
			EPIC PR - Exhibit 991
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 12pt">

			<font style="display: inline;font-weight:bold;">Exhibit 99.1</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<a name="_GoBack"></a><font style="display: inline;font-size:12pt;"><img src="cry-20190911xex99_1g001.jpg" style="width: 2.583333in; height: 0.6770833in" alt="CRY-Tag-Logo-Black-Transparent"></font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;"><img src="cry-20190911xex99_1g002.jpg" style="width: 2.635417in; height: 0.3541667in" alt="Picture 4"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<a name="_DV_M0"></a><a name="_DV_M4"></a><font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">FOR IMMEDIATE RELEASE</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11pt;">Contacts:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;font-size:11pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:261.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;height:1.00pt;overflow:hidden">
						<font style="display: inline;font-weight:bold;font-size:11pt;;font-size: 11pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;color:#000000;font-size:11pt;"></font><font style="display: inline;color:#000000;font-size:11pt;;font-size: 11pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;color:#000000;font-size:11pt;"></font><font style="display: inline;color:#000000;font-size:11pt;;font-size: 11pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;color:#000000;font-size:11pt;"></font><font style="display: inline;color:#000000;font-size:11pt;;font-size: 11pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;color:#000000;font-size:11pt;"></font><font style="display: inline;color:#000000;font-size:11pt;"></font></p>
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 11pt">
						<font style="display: inline;color:#000000;font-size:11pt;;font-size: 11pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;color:#000000;font-size:11pt;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phone: 770-419-3355</font></p>
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:210.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:261.90pt;height:71.00pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:11pt;">CryoLife</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;font-size:11pt;">D. Ashley Lee</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;font-size:11pt;">Executive Vice President, Chief Financial Officer and Chief Operating Officer</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;font-size:11pt;">Phone: 770-419-3355</font></p>
				</td>
				<td valign="top" style="width:210.90pt;height:71.00pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:11pt;">Gilmartin Group LLC</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;font-size:11pt;">Greg Chodaczek / Lynn Lewis </font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;font-size:11pt;">Phone:&nbsp;&nbsp;646-924-1769</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-size:11pt;">investors@cryolife.com</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:left;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font><a name="_DV_M6"></a>
		</p>
		<p style="margin:0pt;line-height:100%;border-bottom:1pt none #D9D9D9 ;text-align:center;font-weight:bold;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;font-size:14pt;">CryoLife</font><font style="display: inline;font-size:14pt;">&nbsp;</font><font style="display: inline;font-size:14pt;">Enters Into Distribution Agreement </font><font style="display: inline;font-size:14pt;">with</font><font style="display: inline;font-size:14pt;"> &nbsp;E</font><font style="display: inline;font-size:14pt;">PIC</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:normal;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:normal;font-style:italic;">Positions the Company </font><font style="display: inline;font-weight:normal;font-style:italic;">for Accelerating</font><font style="display: inline;font-weight:normal;font-style:italic;"> Revenue </font><font style="display: inline;font-weight:normal;font-style:italic;">and Non-GAAP Earnings </font><font style="display: inline;font-weight:normal;font-style:italic;">Growth </font><font style="display: inline;font-weight:normal;font-style:italic;">Over the Next Five Years</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:normal;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:normal;font-style:italic;">Conference Call and Webcast</font><font style="display: inline;font-weight:normal;font-style:italic;"> Tomorrow, </font><font style="display: inline;font-weight:normal;font-style:italic;">September </font><font style="display: inline;font-weight:normal;font-style:italic;">12</font><font style="display: inline;font-weight:normal;font-style:italic;">, 20</font><font style="display: inline;font-weight:normal;font-style:italic;">19</font><font style="display: inline;font-weight:normal;font-style:italic;"> at</font><font style="display: inline;font-weight:normal;font-style:italic;"> 8:</font><font style="display: inline;font-weight:normal;font-style:italic;">0</font><font style="display: inline;font-weight:normal;font-style:italic;">0 a</font><font style="display: inline;font-weight:normal;font-style:italic;">.</font><font style="display: inline;font-weight:normal;font-style:italic;">m</font><font style="display: inline;font-weight:normal;font-style:italic;">.</font><font style="display: inline;font-weight:normal;font-style:italic;"> ET</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;border-top:1pt none #D9D9D9 ;font-weight:bold;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:normal;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:15pt 0pt 0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<a name="_DV_M7"></a><a name="_DV_M9"></a><font style="display: inline;font-weight:bold;font-size:12pt;">Atlanta, GA &#x2013; (September 11, 2019) &#x2013; </font><font style="display: inline;font-size:12pt;">CryoLife, Inc. (&#x201C;CryoLife&#x201D;; NYSE: CRY)</font><font style="display: inline;font-size:12pt;">, &nbsp;</font><font style="display: inline;color:#000000;font-size:12pt;">a leading cardiac and vascular surgery company focused on aortic disease</font><font style="display: inline;font-size:12pt;">, announced today that it has entered into distribution and credit facility agreements with Endospan, as well as an option agreement to purchase Endospan. Endospan is an Israeli-based, privately-held developer of NEXUS</font><font style="display: inline;">&#x2122;</font><font style="display: inline;font-size:12pt;">, the only endovascular stent graft system approved for the repair of both aneurysms and dissections in the aortic arch. The addition of NEXUS to CryoLife&#x2019;s highly differentiated branched aortic stent graft portfolio further strengthens the Company&#x2019;s position as a leader in the growing aortic repair market.</font>
		</p>
		<p style="margin:15pt 0pt 0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:218.5pt;"><font style="display: inline;font-weight:bold;font-size:12pt;">Strategic Rationale for the Transaction</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:12pt;"></font></font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="background-color: #FFFFFF;line-height:150%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
				<font style="margin:15pt 0pt 0pt;font-family:Symbol;background-color:#FFFFFF;line-height:150%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="background-color: #FFFFFF;line-height:150%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">Provides CryoLife with:</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
				<font style="margin:15pt 0pt 0pt;font-family:Courier New;background-color:#FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">Exclusive European distribution rights to NEXUS, the first branched endovascular stent graft system with CE Mark for the repair of aortic arch aneurysms and dissections</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
				<font style="margin:15pt 0pt 0pt;font-family:Courier New;background-color:#FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">Significant cross-selling opportunities with CryoLife&#x2019;s existing JOTEC stent graft portfolio</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
				<font style="margin:15pt 0pt 0pt;font-family:Courier New;background-color:#FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">Immediate access to the $150 million European endovascular aortic arch repair market</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
				<font style="margin:15pt 0pt 0pt;font-family:Courier New;background-color:#FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">Option to purchase Endospan for a predetermined price that survives until 90 days following notice of U.S. FDA approval for NEXUS</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">Page </font><font style="display: inline;"></font><font style="display: inline;">1</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
				<font style="margin:15pt 0pt 0pt;font-family:Courier New;background-color:#FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">Access to potential $800 million overall global market opportunity for endovascular aortic arch repair pending regulatory approvals </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
				<font style="margin:15pt 0pt 0pt;font-family:Symbol;background-color:#FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">Positions the Company for accelerating revenue and non-GAAP earnings growth over the next five years even without exercising the option to purchase Endospan</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
				<font style="margin:15pt 0pt 0pt;font-family:Symbol;background-color:#FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:12pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="background-color: #FFFFFF;line-height:115%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt;margin:15pt 0pt 0pt;">
			<font style="display: inline;font-size:12pt;color:#000000;">Leverages CryoLife&#x2019;s existing 88 person European direct sales organization calling on cardiac and vascular surgeons</font></p></td></tr></table></div>
		<p style="margin:15pt 0pt 0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;color:#000000;"> &nbsp;&#x201C;</font><a name="_Hlk18651267"></a><font style="display: inline;font-size:12pt;color:#000000;">We believe the addition of NEXUS to our product offerings will make a meaningful contribution to our future growth as it gives us immediate access to the $150 million EU market and has the potential to expand our addressable market by over $800 million,&#x201D; said Pat Mackin, Chairman, President, and Chief Executive Officer of CryoLife. &#x201C;NEXUS is another highly differentiated device that, when included in our European channel, further solidifies our position as a global leader in aortic repair, as it strengthens our highly competitive product portfolio in Europe.&nbsp;&nbsp;As we gain experience with NEXUS over the next few years, we may elect to further capitalize on this opportunity with our option to purchase Endospan.&#x201D;</font>
		</p>
		<p style="margin:15pt 0pt 0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;color:#000000;">Kevin Mayberry, Chief Executive Officer of Endospan, commented, &#x201C;CryoLife is ideally positioned to accelerate the adoption of NEXUS in Europe through its experienced direct sales force focused on aortic repair and its complementary JOTEC product portfolio.&nbsp;&nbsp;Additionally, the funding supplied through the distribution and credit facility provides us with the working capital needed to support operations in Europe, as well as to complete the U.S. FDA approval process, which we currently anticipate being completed in approximately five years</font><font style="display: inline;font-size:12pt;color:#000000;">.&#x201D;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Aortic arch disease includes both aortic aneurysms and aortic dissections, which occur suddenly and usually without warning. Approximately 120,000 patients suffer thoracic aortic arch disease annually in the US and Europe, but only about 30,000 receive treatment.&nbsp;&nbsp;While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA) and Thoracic Aortic Aneurysms (TAA), aortic arch disease patients with aneurysms or dissections who receive treatment have had little choice but to undergo open-chest surgery with its associated invasiveness and risks, lengthy hospitalizations, and prolonged recuperation.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Endospan </font><font style="display: inline;color:#000000;">has developed NEXUS, the first approved branched endovascular system to treat aortic arch disease, transforming a complex surgical aortic arch repair into a standard endovascular procedure. It is designed for enhanced intra-procedural and long-term stability attributable to its proprietary geometrical design, which reduces arch manipulation and, hence, stroke risks. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;color:#000000;">Prof. Dr. Nicolas Doll, Sana Cardiac Surgery, Stuttgart, Germany, commented, &#x201C;NEXUS is a highly differentiated stent graft system that allows physicians to repair aneurysms and dissections in the aortic arch through an endovascular approach. NEXUS is especially important for elderly patients who are not suited for open surgery, and for patients with a prior Type A dissection that was repaired in an open surgical approach.&#x201D; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">Univ. Prof. Dr. Hubert Schelzig, Clinic for Vascular and Endovascular Surgery, University Clinic D&#xFC;sseldorf, Germany, commented. &#x201C;The NEXUS system has the potential to cross the next frontier in aortic surgery, namely a safe, therapeutic, minimally invasive procedure in aortic arch pathology. Not only does it provide a platform to treat the aortic arch, but it is a perfect fit with </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">Page </font><font style="display: inline;"></font><font style="display: inline;">2</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;">CryoLife&#x2019;s highly differentiated and comprehensive portfolio of products that treat the entire aorta.&#x201D;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">Terms of the Agreements</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">Under terms of the agreements, CryoLife will acquire the European distribution rights for Nexus and an option to purchase Endospan for a total upfront payment of $10 million. Additionally, CryoLife will provide up to $15 million in additional debt financing to Endospan subject to Endospan&#x2019;s progress on its U.S. clinical trial in support of an FDA approval for NEXUS.&nbsp;&nbsp;CryoLife expects to finance the acquisition of the distribution and option rights and debt financing out of available cash on hand.&nbsp;&nbsp; </font>
		</p>
		<p style="margin:15pt 0pt 0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">Under the purchase option, CryoLife has the right to acquire Endospan at any time until 90 days after receiving notice of U.S. FDA approval of the NEXUS stent graft system for a total consideration of $250 million, plus a guaranteed $100 million payment and up to an additional $100 million based upon commercial success of NEXUS in the first year post-option exercise.&nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:15pt 0pt 0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">The distribution agreement, credit facility, and securities purchase option agreement have been approved by both companies&#x2019; boards of directors and Endospan&#x2019;s Security Holders.&nbsp;&nbsp;The purchase obligations of the securities purchase agreement will become effective if, and only when, CryoLife exercises its purchase option and are subject to customary conditions to closing.&nbsp; </font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">Financial Commentary</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">The Company does not anticipate the transaction with </font><font style="display: inline;font-size:12pt;">Endospan</font><font style="display: inline;font-size:12pt;"> to have a material impact on its 2019 financial guidance. Management will update its 2019 financial guidance, if necessary, in its third quarter financial conference call.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">Advisors</font><font style="display: inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">In connection with the transaction, Vinson &amp; Elkins, LLP is acting as lead legal counsel to CryoLife.&nbsp;&nbsp;GKH Law Offices is acting as lead legal counsel to Endospan. </font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;font-size:12pt;">Webcast and Conference Call Information</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">CryoLife will hold a teleconference call and live webcast tomorrow at 8:00 a.m. Eastern Time to discuss the proposed transaction, followed by a question and answer session hosted by Mr. Mackin.</font>
		</p>
		<p style="margin:15pt 0pt 0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 8:00 a.m.&nbsp;&nbsp;A replay of the teleconference will be available September 12 through September 19 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415.&nbsp;&nbsp;The conference number for the replay is 13694487. </font>
		</p>
		<p style="margin:15pt 0pt 0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">The live webcast and replay and the accompanying presentation can be accessed by going to the Investor Relations section of the CryoLife website at </font><font style="display: inline;font-size:12pt;">www.cryolife.com</font><font style="display: inline;font-size:12pt;"> and selecting the heading Webcasts &amp; Presentations.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;font-size:12pt;">About CryoLife</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;font-size:12pt;">Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair.&nbsp;&nbsp;CryoLife markets and sells products in more </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">Page </font><font style="display: inline;"></font><font style="display: inline;">3</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;color:#000000;font-size:12pt;">than 100 countries worldwide.&nbsp;&nbsp;For additional information about CryoLife, visit our website, </font><font style="display: inline;color:#0000FF;font-size:12pt;text-decoration:underline;">www.cryolife.com</font><font style="display: inline;color:#000000;font-size:12pt;text-decoration:underline;">.</font><font style="display: inline;color:#000000;font-size:12pt;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;font-size:12pt;">About </font><font style="display: inline;font-weight:bold;font-size:12pt;">Endospan</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">Privately held Endospan, headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of Aortic Arch Disease including aneurysms and dissections. Endospan has received CE-Mark to commercialize in Europe the NEXUS&#x2122; Stent Graft System, the first endovascular off-the shelf system to treat Aortic Arch Disease which affects a greatly underserved group of patients diagnosed with a dilative lesion in, or near, the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation.&nbsp; </font><font style="display: inline;color:#000000;font-size:12pt;">For additional information about </font><font style="display: inline;font-size:12pt;">Endospan</font><font style="display: inline;color:#000000;font-size:12pt;">, visit their website, </font><font style="display: inline;font-size:12pt;">www.endospan.com</font><font style="display: inline;color:#000000;font-size:12pt;">.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;color:#000000;font-size:12pt;">Forward Looking Statements</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;font-size:12pt;">Statements made in this press release and the accompanying presentation that look forward in time or that express management&#x2019;s beliefs, expectations, or hope are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made.&nbsp;&nbsp;These statements include those regarding the worldwide, including international and US, market opportunities for endovascular aortic arch repair products; and the number of </font><font style="display: inline;font-size:12pt;">patients that suffer thoracic aortic arch disease annually in the US and Europe and the number of those patients who receive treatment</font><font style="display: inline;color:#000000;font-size:12pt;">; the ability to leverage CryoLife&#x2019;s existing direct sales force in Europe and to create significant cross-selling opportunities with CryoLife&#x2019;s existing JOTEC stent graft portfolios; the positioning of CryoLife for accelerating revenue and non-GAAP earnings growth over the next five years;</font><font style="display: inline;font-size:12pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:12pt;"> and the CryoLife loan to&nbsp;&nbsp;Endospan will provide Endospan with the working capital needed to support operations in Europe, as well as complete the U.S. FDA approval process; and the anticipated completion of U.S. FDA approval process in approximately five years.&nbsp;&nbsp;They also include our beliefs that</font><font style="display: inline;font-size:12pt;"> the addition of NEXUS to our product offerings will make a meaningful contribution to our future growth; give us immediate access to a $150 million EU market and has the potential to expand our addressable market by over $800 million; the distribution agreement further solidifies our position as a global leader in aortic repair and strengthens our highly competitive product portfolio in the EU; as we gain experience with NEXUS over the next few years, we will be able to further capitalize on this opportunity by exercising our option to purchase </font><font style="display: inline;color:#000000;font-size:12pt;">Endospan </font><font style="display: inline;font-size:12pt;">at any time up until 90&nbsp;&nbsp;days following notice of U.S. FDA approval of NEXUS</font><font style="display: inline;color:#000000;font-size:12pt;">.&nbsp;&nbsp;These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. These risks and uncertainties include that the estimated market opportunities may be incorrect or may change over time; we may be unable to capitalize on cross-selling opportunities of the distribution agreement in the EU at all or as well as anticipated and anticipated portfolio synergies may be less than expected or may not materialize at all; competitive dynamics may be different than anticipated; regulatory approvals may take longer than expected or may not be obtained at all; we may be unable or unwilling to exercise the option, if US regulatory approval is not secured for NEXUS or not secured within the anticipated timeframe or even if US regulatory approval is secured for NEXUS. We may also be faced with unforeseen risks and uncertainties related to Endospan&#x2019;s business, particularly if the information received by CryoLife during the due diligence phase of this transaction now or upon exercise of the option is incomplete or inaccurate. </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">Page </font><font style="display: inline;"></font><font style="display: inline;">4</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;;font-size: 12pt"><font style="display: inline;color:#000000;font-size:12pt;">These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2018, and our subsequent filings with the SEC. CryoLife does not undertake to update its forward-looking statements.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">Page </font><font style="display: inline;"></font><font style="display: inline;">5</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cry-20190911xex99_1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cry-20190911xex99_1g001.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_X0!:17AI9@  34T *@    @ ! $Q  (
M   4    /E$0  $    ! 0   %$1  0    !   +$E$2  0    !   +$@
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M/#/C)\6]7\.^((_#WANXCMI[=%EO+DQ!VW,,K& ZE<;2K$C.=P&1@@U_A#\7
MM?\ $'BR+P]XAFCO!=I(T%PL"HZNJ[MK;=J[-J/_  DY(YQTD^.?@'1IKQ/$
MW]NV.DWUQA+B*^D<BX"A5#QJBLY91L!"J1C!.W!+>7Q:1/X1\/-XLTCQ+I5Y
M</*+&%K!Y?.MO-24-(0P1HV*QLJ[E.0Y88*JU 'TGXJ^*GA3P?JD6F:G>R->
M,Z"6*WC,A@1L_._8 #!VC+8((4@UL>+?%>F^#/#\NLZH9#!&ZHL<6WS)&8XP
M@8@$XRQ&>BD]J^4/AS\/)OB%JEQ:1:K:6"6R!Y?,!>5E.1E(^-P#!0Q)&-PZ
M]*]_\9?!ZQ\1>#M+T>RU"[AN-&MWBL)+B7S%<MLR)203@[ !MP%SPI "T =9
MIOCCPUK&AW>LZ?J\%Q8V<337+(&WPHNXDM'C>O",1D<XXS7S9JOQW\<7NJ7%
MQ8:C'I]H[YBM4MXI!$O8;G0ECZGU)P , <7(^J>#_$.H64%YY=U:RR6=P83F
M.8*^&1E88>,E>588(ZBND\7> M'\/>);O3X/&NC&!'/EK-Y\DL8R04D\F)U#
MJ001D'@'"YQ0!]'_  N\:S>._!PU2[@CAO(KA[>X6)"L9888%,LQQM=<Y/7/
M;%=I7%_"OPW8^&/ =G:6-_::@9G>>XO+23?%+*3M.TY(PH4)QC.S) )(KM*
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M\QQZ!XA^.'CE_#FC7$-A!I#7GFRB_A02)=*KE-J*X8)M(^8$EC\I^4'!\_\
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M!EVL20\F1UR,18/ ^8]>P!Z_XS@AM?AIXAM[>*.&"+1[E(XXU"JBB%@  .
M.U?$E?>>K:;#K.C7VEW#2+!>V\EO(T9 8*ZE21D$9P?0U\*7]C<:9J-S87D?
MEW5K*T,R;@=KJ2&&1P<$'I0!ZQ^SC_R4/4/^P5)_Z-BKZ?KX@\#^)/\ A$?&
MFEZX8_,CM9?WJ!<DQL"C[1D?-M9L9.,XSQ7VGI6JV.MZ7;ZGIES'<V=PF^*5
M#PP_F"#D$'D$$'D4 7***Q_$_B?2_".AS:OJ\_E6\?"JO+RN>B(.[''Z$D@
MD 'RQ\;?^2O:[_V[_P#HB.O/ZT-<UF\\0ZY>ZO?OONKN5I7P20N>BKDDA0,
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MW>@ZOHNFWFK6SM<1/<:=$Y:W.T8W[<DJY/WN<,N,@87V/_A!/!__ $*FA_\
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MI&H2WEX ?CG#G.21][.3EP*^DZCG@ANK>6WN(HYH)4*21R*&5U(P00>"".U
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M;^(?BO\ V%\2M/\ !_\ 8$\GVN6WB^V2S>6O[U@-R+M.]1G&<CY@P[9KTB@
MHHHH ***IZMJ4.C:-?:I<+(T%E;R7$BQ@%BJ*6(&2!G ]10!<HKYP;X[^,+G
M49/^)?8Z;;P[+@"6RFE589"JH9V#;A'ME5]Z+EF" ##XKM_#7QUT&XTE3XK/
M]B:FNW, AFD$J&-665<(=JMN) )/&#DYS0!ZQ1110 4444 %%%% !1110 44
M44 %%%% !1110 5X_P#"#_DH?Q._["H_]&W%>P5XA\,]=T?1/B'\2?[6U6QL
M/.U4^7]KN$BWXEGSC<1G&1T]10![?7B_@CXG^-?&WASQ)/8:3I4VKZ?]E^QP
M(K(DGF.P?<7D[*I(Y'X]*]0L?%GAO4[R.SL/$&E7=U)G9#!>QR.V 2<*#DX
M)_"O&/V9?^9I_P"W3_VM0!AZ5JOQ(3XRZY=VGA_39/%$EDJWEDT@\J.+$.&4
M^:!G C_B/WCQZ=_XM^+.M)XQE\*>"-!CU;4+9U6XG<F2-2>&7"$;0K,@+LP"
MG<".]1^'O^3H?%G_ &"D_P#0;6O-)-*FA^-WB:QO/%DGA&6:XN)4O5D(#J[B
M5$9E=0H9"&Y;J ,9P* /0[;XJ^,?#OBW3=,^(.@6.FV.H?)'<V[8$9+ ;RYD
M9"JG[PR" P;T#>T5\N>(O#>@7>J:=I^L?&.359)'VQ2/ US%;AL_,TGG%4!*
M*#SD94D!>1]1T <_X[_Y)YXF_P"P5=?^BFKP3X3?%G0? GA6ZTO5+34IIY;U
M[A6M8T90I1%P=SJ<Y0]O2O>_'?\ R3SQ-_V"KK_T4U>.?!_P1HOC#X4:U;W]
MC:&\EO988;YH TL!\J(J5;AL!CG;D \@\$T 9>D3W'Q;^.5IKVG:9]ATW3I8
M9I9Q&"Q2)BR&4Y ,CE0HP3A0/O!":[.Z^*_BOQ'XEO\ 2OAYX<M-1@TYV6:\
MN90R2C(4,I#HJ@D-CYF+#D 8(K,^!_B2\\/ZQ??#OQ#'/;7R2M)9Q2*6VMM+
M2)G) 4@;UP-IRYR=RY\W^'>F22:CJUA<^.Y_!=U#M#H[-#YQ4L&5CYB ,A/W
M3S\QP.#0!['X7^*/B./QXGA+QWHUII=W=(IM)(#M3<02 278,&QM!4_>&W!)
M.VGJ7Q5\8ZMX^U3PWX(T"QN_[-WI+]M;#N8WV.X/F(H7<0 .3W[X'*:-X<TC
M4?B]H]I+\1[O7]3LWBN8IVM3-%)Y3>;Y*S><V#M#-P"HR1G=\M:FN^%O VJ>
M.=3U+0OB)_PC6LV]W+]M$S&/;,Q*OY3.T9ZB3=M9A\W&T8! .C\)?$+QUXJ\
M)^(I8/#=H->TVXBAMXW1XHI&+8DC8.XPZ*"3\X^\O [\!X$U7XD6WBKQC+X?
M\/Z;=ZA->[M5BFD 6"7?+\J?O5R-QD'5N@Y]>H^"GC'Q'?>+]4\+:OK$>KVE
ME;RO%=;_ #26295RDO5T;>2"V> N,#BCX:^)-%T/XE_$:#5M4M+![G4V>$W4
MHC5PDTP;#-@9&]>,Y/..AP :?C7XP:IX8_LO0K71H+OQ5<VD#W42OOCMYWV_
MN@B,6=C\V!N'#(06S69J_P 4_B7X,>TN_%GA#34T^9V3_1Y""S;<@>8LD@4]
M\$<@-CH2,_4=3L=!_:;M];U*2T72]1MXY;6^:7<@1[?RUE4HV "RLN6R,$MQ
MPPZOXN^-_"US\,]5LK76=*U&ZNO+BAMX;H2DMO5MV(VR-H4L"?ER #G." 7/
M'OQ.FT7X<Z1XK\.1VEPFHW$:!;H%PJM&[$'8XPZLFTC)P014?@GQ=\1?$^L6
M-[?>&+&R\+7GF2+/N_?+'M8Q\&3)R0OS; "#D  @UYQXNL;C3_V9?",-U'Y<
MC:@)@-P.4D%Q(AX]593[9YYKZ3@@AM;>*WMXHX8(D"1QQJ%5% P  .  .U '
MC_@3XLZ]XH\*^,=4O;338Y]%LOM%LL,;A7;9*V'RY)&8QT([UD:!\6/B?XO1
M3X>\)Z;<")")YV1UB+ANBLTBJ#M9/DR3U;H<#F_A!_R3SXG?]@H?^BKBO5_@
M58V]I\*--F@CV27<L\TYW$[W$C1@\]/E11QZ>N: #X;?%#_A*[/5+;Q!!!I6
MKZ3N>[1F\I/+!.6VN=R[,8?/ X.?FP.4L_C#XW\9:S=0>!?"EI-:6R;G-ZQ+
M8+$*S-O1%)&/DRQX;!(''-^&+&XU/XI_%&PLX_,NKK3]6AA3<!N=IU"C)X&2
M1UK8^ /C7P_I'A[4=$U74H+"Z^UM=H]W(L<<B,B)@.3C<"O0XX((S@X +%K\
M8O'%OXRT?PUKWAVQT^ZNM0C@G+0RC=$\BQ@QY?!P1)\X+*W&!P<^[U\^?$+Q
M1HOB'XS^"+?1Y+2[-E>VXFOK=PXD+S(1'N P0H&<@D9D8<$&OH.@ KQ_Q#_R
M=#X3_P"P4_\ Z#=5[!7C_B'_ ).A\)_]@I__ $&ZH U/'OQ.OM#\2VOA/POI
M,>J^(+E%;#R92$DY"LJD'.T,QR5"@JV2,USEU\6O'O@_48#XX\'P1:;+M7S;
M'/RDGL^]T9MJN?+)4G@Y Z\?\0;60?M#7 N-:G\.1W7DF+50K#RP;=4W @K\
MI8%"V0!\V3@&H_%^C:1#;V-OK'QBN];@GN!B.&,WJP8&#*X^T$* &[98Y. >
M< 'K?Q*^+-GX(TZQ_LZ*#4[[48FEM]LX\M(\?+*VW)922, 8# -\PQ7,7/Q#
M^+ND6=GJ>J>";$V$TL2%(8W\YMY&U=HE9D8Y"C<O#$ C)P>?^(^F?\(=\0_A
MU<WTV=,TZTLK9KS;][[-+F1M@)885E..>N!G!KV/4OB=X(TJW6>X\3Z:Z,^P
M"UF%PV<$\K'N(''7&.GJ* /'/C%J%Q:?&3PGJ46G3RW45I9SK89'F.XN)&$7
MR;AN)^7Y=W/3-=!J'Q2^(O@Z\L+GQIX4L8-(GE,<CV9W/T[,)64-W"MC=M(!
M')&7\3)X;KX^^!;BWECF@E2P>.2-@RNING(((X(([UW_ ,<8(9OA)J[RQ1N\
M+P/$S*"4;SD7*^AVLPR.Q([T 9?Q/^*&L>!]1T.ZTV#2M0T34HO,!+.9)-I!
M;:ZG:%*.FUL-SDXQC.!JOQ2^*/AC3K+6/$/A32K?3)Y8TQEDD;<"VW'FLR,5
M5OO+P>H[57\2?\T+_P"W;_VUKO\ XV_\DAUW_MW_ /1\= $GB[XHZ;X6\%:9
MXB6TDN7U1(WL[-Y5B=E90Y+=<!5(R0&Y*COFN$_X63\7?^$7_P"$D_X1+2O[
M)\KS_.\I]WEY^_L\[?MQSG&-OS=.:P_B>JP^!?A7?W5A)>:?!91BYC#,BN#%
M ?++C[I94?!Z\$CI7L\_Q,\&PZ-+J:>(M-G1+<W"P1W48G<!=VT1LP.\]-IP
M<\'% 'GGBCX@6?Q!^ GB*^AM_L=U;RP17%H9A(4_?QE6!&"5(Z$@<JPYQFK?
M@OQG8^!?V?-'U>^CDF)>>&W@3@S2F:4A<]%&%))/0 XR< ^6>%;&XC^"'C^_
M:/%K-+80QON'S.DP+#'7@2)^?L:D\4Z;-+\"/ >J*T?D6]Q>V[J2=Q:25V4C
MC&,1-GGN/P /0(/B%\8[KP_%KEOX-TV:PE0/&T<$C2.I. 1$)MY!ZYV].>G-
M=W\,OB);_$'0Y)3#]GU.SVI>PJ#L!;.UT)_A;:W!.1@@YX)L6/Q2\%7NAQZL
M?$-C;QM$96MYYE6=,9RIBSN+#!& #GMD$9\D^%NB3>*+CXC7NC>98Z7J5O<6
M=G;21F. M,7*9VY4&-<# !P)>/< WV^+?B_Q7XEO;/X=^'K34-/LT&ZXO%*E
M^2-V3(@4'^%3\Q"D\<A:EK\8O'%OXRT?PUKWAVQT^ZNM0C@G+0RC=$\BQ@QY
M?!P1)\X+*W&!P<Q_ CQ=HOAW1M5\.:[>QZ5J$5Z]P5OV$*D;40KEB,.K(<J<
M'GC.#B/XA^)_#_B#XO\ @6'1IX+RXL]0@%S=P;61@TT91!(/O;?F/' W]<[@
M #T/5?&NI6/QET/P?%!:'3[^R:XED9&\T,!,<*=V,?NUZ@]36/X]^*>I:3XL
MM?"'A#2X]2UYW7SEG1BB;EW!1@KD[2&+$[5'7/.VGXA_Y.A\)_\ 8*?_ -!N
MJX#X@VL@_:&N!<:U/X<CNO),6JA6'E@VZIN!!7Y2P*%L@#YLG - '67GQA\;
M^#=9M8/'7A2TAM+E-R&R8AL!@&96WNC$#/R94\KD@'GH_B9\3=4\+>(=)\->
M'M,@N]7U#8X-W_J\.YC1!AE^8L.I(  '7/R^6>+]&TB&WL;?6/C%=ZW!/<#$
M<,9O5@P,&5Q]H(4 -VRQR< \X[#QSX3\ 7SZ+X:U7Q='IOB33-,ALTN67]T8
MT7(\T$[$) <@;U/SC.[Y10!M^$?'?Q N_B OASQ1X6@MH?*+RSVD4FV#*LR,
M7W.A5BC+U'S9YRI%=IX_T!O%'@/6='B61IY[<M B,JEY4(>-<MP 650<XX)Y
M'6O%-$\5:[X.^*NE:(GC;_A+-(U*6&-Y!="8?O"T8R27\ME8[BJM\P"Y//'T
M?0!\B:U>P^+O$'B[6M7OI-$G73(5DMF(C::\00J8/)+%V0O&_KLPC-C&#&O@
MWQE\0[6SUG2?#V;&&T@L(Y/-AB\SR(EC+98J7R5/)SC[N3LX^L[S2=-U"XM;
MB]T^TN9[1]]M)-"KM"V0<H2,J<J.1Z#TJY0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %</?_"#P)J>HW-_>:%YEU=2M-,_VN<;G8DL<!\#))Z5W%%
M''Z)\+?!OAS6(-6TG1OL]]!N\N7[5,^W<I4\,Y!X)'(K0\,^"?#O@[[5_8&G
M_8_M6SSOWTDF[;G;]]CC&X]/6N@HH Q[?PMHUIXHN_$L%GLU>[B$,]QYKG>@
M"@#:3M'W%Z#M]:S_ !9\/?#7C7;)K-AYEU'$T45U%(T<D8/N#AL'D!@0"3QR
M<]110!Y_X8^#/@[PO>0WL-I/>WT$OFPW%[+O,9Q@850J<'D$J2#SG@8] HHH
M KW]C;ZGIUS87D?F6MU$T,R;B-R,"&&1R,@GI6?X<\+:-X1TZ2PT.S^R6LDI
MF9/->3+D $Y<D]%'Y5L44 <WJ/@'POJOB6W\17FDQOJUN\;I<K(Z'=&<H6"L
M Q&!R0> !T %9?C'X3^%O&UY]NOX)[:_.T/=6<@1Y%4$ ,""IZCG&[Y5&<#%
M=Q10!Q?A+X5^%/!MQ%>:=922ZA&C(+VZD+R88\X'"*<?+E5!QD=SG/\ %'P5
M\(>*=4?4IHKNPNY79YWL90@F8XY965@#P3E0,EB3DUZ)10!S_A/P7H7@K3FL
M]%M/*\W:9YG8M),RC +,?Q.!A02< 9-<OXG^"/A/Q1KDVKS-?65Q/S,ME(B)
M(_=R&1OF/?&,]<9))](HH YO5O /A?7=&T_2=2TF.>STY%2T4R.K1*%"@!PP
M;& ,@GG )R0*Y?1/@1X(T>X\^:VN]3<.CQB_F#*A4Y^Z@4,#QD,&!Q]<^F44
M 8_B/PMHWB[3H[#7+/[7:QRB94\UX\. 0#E"#T8_G6Q110!R^C_#OPKH.G:I
M8:9I?D6NJ1>3>)]HE;S4PPQEF)'#MTQUK8T31-.\.:/!I.DV_P!GL8-WEQ;V
M?;N8L>6))Y)/)K0HH YNR\'^&_#FLZEXFLM-DBU"Y25[J:-YI6D#,)'Q'DY)
M8 X5<]AZ5XI<^)?A!X\EU*YU_39_#U\9<0W=N'+SH6+>81&K)YA.=VY6^\,,
M?X?H^OG3]H[2=-T^XT"XLM/M+:>[>[>YDAA5&F;,1RY RQRQY/J?6@#+AA\.
MZY\6O#.G?#K2-VF:==Q7MS<JDF]\.C2,S2MN\M550 <?,6P#N&?I^O-_@;86
M=O\ "W2[R&T@CNKKS?M$R1@/+MGD"[F'+8' STKTB@ K'N/"VC7?BBT\2SV>
M_5[2(PP7'FN-B$,"-H.T_?;J._TK8HH Y_Q9X+T+QKIRV>M6GF^5N,$R,5DA
M9A@E6'X'!RI(&0<"N3T3X$>"-'N//FMKO4W#H\8OY@RH5.?NH%# \9#!@<?7
M/IE% &7K_AS2/%.EMINM6,=W:%P^QB5*L.A5E(*GJ,@C@D=":\_TW]GWP18W
M#2W U+4$*;1%=7(50<CYAY:H<\8ZXY/'2O5** .;O? /A?4-9TW5KC28_MFF
M)$EFT<CQK"L;%D 16"X!/3'MTK4UO1-.\1Z//I.K6_VBQGV^9%O9-VU@PY4@
MCD \&M"B@#G[GP3X=O/["\_3]_\ 8.W^S?WT@\C;LQT;YO\ 5I][/3W-:&MZ
M)IWB/1Y])U:W^T6,^WS(M[)NVL&'*D$<@'@UH44 9<WAS2+GPT/#L]C'+I(M
MUMA;.2P$:@!1DG.1@8;.00#G/->?P_L^^"(M4-VXU*: NS?8GN0(@#G"Y50^
M!GCYL\#)/.?5** ,.;P?H$_A,>%WTV,:*$5/LJ.R#"L''S*0V=PR3G).<YR:
MDL?"NA:?X<C\/0Z9 ^D)G%I.#,ARY?G?G/S'//2MBB@#RN;]GWP1+J@NT&I0
MP!U;[$ER#$0,97+*7P<<_-GDX(XQZ)HVAZ7X>TY+#2+""RM5P=D*8W$ #<QZ
MLV ,L<DXY-:%% 'SA<^)?A!X\EU*YU_39_#U\9<0W=N'+SH6+>81&K)YA.=V
MY6^\,,?X<_=X1U;XJ^$-)^'ND[+6TU!;J>Z+N#<8*.^/-.[:B1,0">26PO=M
MC]I2PL[>\\/WD-I!'=77VG[1,D8#R[1"%W,.6P.!GI7?_ VPL[?X6Z7>0VD$
M=U=>;]HF2,!Y=L\@7<PY; X&>E '87'A;1KOQ1:>)9[/?J]I$88+CS7&Q"&!
M&T':?OMU'?Z57\6>"]"\:Z<MGK5IYOE;C!,C%9(688)5A^!P<J2!D' KH**
M/-_#WP.\%:!>-=/:SZI)_ -2=9$3@@_(%56SG^('& 1@UN>,_ASX<\=(C:O;
M2+=Q)LBO+=]DJ+N!QG!##KPP.-S8P3FNLHH X?P=\)_"W@F\^W6$$]S?C<$N
=KR0.\:L "%  4=#SC=\S#.#BNXHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>cry-20190911xex99_1g002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cry-20190911xex99_1g002.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" !. D0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **,\]:* "BBB@ HH) &32;U_O"@!:*0LH&2PI:
M"BBB@ HHSCK1N'K0 44;AZT4 %% (/2B@ HHHH **0NJ_>8#ZT!T;[KJ<],&
M@!:*** "BBB@ HHHH **** "BD>2./&^0+GIDXI!+$>DJ\#/WJ '44 @C(HH
M **** "BDW+G&X4%T49+8^IH 6BD61-VP."<9Z\TM !1110 444@9"<!AD>]
M "T444 %%%% !12!T/1A1N4=6% "T444 %%%% !12,RJ-S, !U)-"NK#*L#]
M* %HHHH **** "BD+*#@GF@.A. XH 6BBB@ HHH) ZT %%&X>M&<]* "BBB@
M HHHH **** /R'_X.=_B[^WS^PYX(\,_M8?LB_MX^,/#%OXD\36_AZY^',&F
MV4]LTIM99%GM&-LT@8B!BZ.S9+94KC:9O^#;C_@O9K?[?.BW7[)/[7WBVWD^
M+6BPR76B:U-&D!\2V"C+@J@"_:8N2P4#>GS 95J]V_X*36K?&K_@J_\ L8_L
MVI>>;9:+KGB+X@:_IS6RRJZV%DL-F[!CP/,FF7.#UXYK\M_^#@__ ()%_$G_
M ()D?M&:7_P5-_X)\07F@^%?[=AO]5@T*#'_  B>L>86$ZJ,@6<QXVD;%=BA
M^6110!^D/_!3SP_^U=#_ ,%-_P!G#X=? 7]O7XC^"]'^+VJZM:^+O#&CWFGB
MVT_3M/LX)GELTEM)")I3O&^7S0&)*[1E3^BV@:9-HNB6>C7&K76H/:6L<+7U
M\RM/<%5"^9(5"@NV,L0 "2< =*_%W_@D;_P5 U7_ (+1_P#!4GX6?$GQ!\);
MS2-2^#/P&UO_ (2RX6\5[*36+NZM+8W,"@ JKQY(4Y(+L!D1[C^U] !1110!
MA_$7PGJ7CSP+JO@[2?&^K^&;G4[.2WAU[06A%[8%ACS83/')&)%Z@LC#/8U_
M-?\ L8?M)_\ !2S]JW_@LO<?\$WH/^"E_P :QX'A\>:Y:7VN67B:+^T?[.TU
M+IO,6;RFCC9UB X386=?E.%%?TJ^/O$<'@[P/K'BZ]N$AATO2[B\FFEDVK&D
M4;.6)[ !<FOY=_\ @V>_9^U7]N/_ (*E^./B?>?%'QGX+DTSP]JNOR:SX$U4
M65XMQ=WD:B(R^6Z>6PEEW(5PV!Z4 ?M;)_P3%_:)^'?Q^^'_ (A^"W_!8?XX
M:FFAZW#JGC+P1\3/%5KJJ:SI"OMD2..WMX"@9@$W,K+\QY! !^\5!55!.>.M
M?)7[(7_!,O7OV7OVXOB5^UOXA_:9\8_$&+QGX4TW1=&M_&^IM>7NF1PR22W"
M^: D?E-(4*(L8V_/Z\_6U !1110!\Q?\%:_@=\>/C'^QAXMU+]F;]H7QI\/?
M'GA31[O6?#5]X.U7[-_:%Q#"S_9+D;29(G"E0 058JV3C:?RJ_X-=_VU_P!H
MS]O'XH?&7X&_M5_MK?%75O$P\$*WA?SO% (L+9Y#!=75NLJ.%NXGDMRCE6"@
MG@\U^]\\*7$30R*-K<,".HK^4[Q_X[U7_@W_ /\ @X:\4>+=#\&WFH^%]-\1
M7=S!X?TZ;RGOM#U6$S101L<@F,S*%!S\T&#SG !Z'XW_ &M_^"@G[(7_  7"
ML?V%/VG?^"D?QFF^&ME\5+.PN-1_X2YH[F?1KIT>TDD?84R4EA$I"@'$F N1
MC]I_^"X'C+Q'X _8 U#4OAG\8/&?A3Q[>ZQIVD?#.?P/X@^PW>J^(+Q_LUG9
MNVUO.A9I3(\>,D19!!7-?A%_P7<_X)U?M"_"CX0?#C_@JE\;]<UJX\<?&C7;
MJ^^(.GS;1#X9N[A1<Z;91;?F01VJ&+G.&M\'!(!_3S_@DG^T!\2_^"WWQ!^%
MG[3_ ,6OAY=Z7\-_V=_#-O;6MM?R(Z>(/B&8$CFU--H'[FWMF)C!&5DN3Z'(
M!^@W[!_[/GQ1_9I_9JT'X>?&SX_^*OB5XN:WCN_$OB;Q9JGVJ5KUXD\Z* [0
M4ME=3L0Y(!))))KV6@# P** "D=BJ;@,X[4M!&>"* /YX/B9_P %,O&7_!0;
M_@O-<_L7_M<_M0>*OA/\!?#GC#5?#]CX<\,>)KC0TU.YMM\5NE]<0.K,T\T8
MR7.U P5=N2Q_6GX'?\$GO!'[+/[2_A;XV_LQ_M"?$3PYX5TZSO;?Q;\,-1\7
M7NJZ-X@$L#K;S>7=3/\ 9YH97\P.N=V,8&23\A?\%Y_^#;CP)^VW_P )%^V1
M^R2PT'XO_9S>:MH><6/BIXU R23_ */=%5XD'RR$ . 27KQ/_@TA_P""I_[1
M_P 8?'?B3_@GU^T%XLOO$ECH'ALZMX.U'6)&DO-.2&9(I[-Y&RTD?[U"@<Y3
M8R@X(  /W?HHHH **** "BBB@ HHHH ^6_\ @LQHMM<?\$W?BIXU;XB>,_"]
M]X/\(ZAKVAZMX&\57.D7D>H6]K*;;=+;R(9(O-9"T3$JV <9"X_%_P#X($?"
M3]M+_@J#\$/CQXX^*O\ P4X_:,\.2>#-.M+;PAJVC?&+5(H8]2D@GD+3QF5O
M.C5(80RY4[7X.<$?J-_P<[?%1OA5_P $8_BK+!<(MQXA.FZ%#&S &07-]")
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MP4R_9_\ B+\9/VS/V^?VB=?M]/\ $L6B:-I=K\=M>LXH@L"S2R/Y5RI<MYJ
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MVE_&7[1G_!._Q--\4OB9KGBGQ5HOQ-O8=6U/Q'KEQ?WDBRVUO-&6>=W;;AF
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MB_"G0H+][_P5\)?[6FN=8GEM)(8%N9=0MU^2.1UFRC+S&!M-?9E%% !1110
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M4 <%^S%\+?'?P5^ 7A/X5?$[XP:MX^\0Z'H\=MK/C+7/^/K5[@9+SN,G&22
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cry-20190911.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 6.32.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/11/2019 4:07:24 PM-->
<!--Modified on: 9/11/2019 4:07:24 PM-->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" targetNamespace="http://www.cryolife.com/20190911" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:cry="http://www.cryolife.com/20190911">
  <annotation>
    <appinfo><link:roleType roleURI="http://www.cryolife.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation"><link:definition>00090 - Document - Document And Entity Information</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:linkbaseRef xlink:type="simple" xlink:href="cry-20190911_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all"></link:linkbaseRef><link:linkbaseRef xlink:type="simple" xlink:href="cry-20190911_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all"></link:linkbaseRef></appinfo></annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"></import>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"></import>
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"></import>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"></import>
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"></import>
  <element id="cry_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element></schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cry-20190911_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 6.32.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/11/2019 4:07:24 PM-->
<!--Modified on: 9/11/2019 4:07:24 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cry-20190911.xsd#cry_DocumentAndEntityInformationAbstract" xlink:label="cry_DocumentAndEntityInformationAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="cry_DocumentAndEntityInformationAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cry_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cry_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre Commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre Commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label></labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cry-20190911_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 6.32.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/11/2019 4:07:24 PM-->
<!--Modified on: 9/11/2019 4:07:24 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cry-20190911.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"></roleRef>
  <presentationLink xlink:role="http://www.cryolife.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <loc xlink:type="locator" xlink:href="cry-20190911.xsd#cry_DocumentAndEntityInformationAbstract" xlink:label="cry_DocumentAndEntityInformationAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637038148440329312"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637038148440329312" order="1" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637038148440329312"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637038148440329312" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637038148440329312"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637038148440329312" order="3" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637038148440339287"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637038148440339287" order="4" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637038148440339287"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637038148440339287" order="5" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637038148440339287"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637038148440339287" order="6" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637038148440339287"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637038148440339287" order="7" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637038148440339287"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637038148440339287" order="8" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637038148440339287"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637038148440339287" order="9" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637038148440339287"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637038148440339287" order="10" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637038148440339287"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_637038148440339287" order="11" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637038148440339287"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637038148440339287" order="12" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637038148440339287"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637038148440339287" order="13" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637038148440349565"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637038148440349565" order="14" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637038148440349565"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637038148440349565" order="15" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637038148440349565"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637038148440349565" order="16" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637038148440349565"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637038148440349565" order="17" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637038148440349565"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637038148440349565" order="18" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637038148440349565"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637038148440349565" order="19" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637038148440359557"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637038148440359557" order="20" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637038148440359557"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637038148440359557" order="21" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637038148440359557"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cry_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637038148440359557" order="22" use="optional"></presentationArc></presentationLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " ")@2M/R]^V>>X    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+/:L,P#(=?9?B>R$XA4)/FTM%3!X,5-G8SMMJ:Q7^P-9*^_9*L
M31G; ^QHZ>=/GT"-CE*'A,\I1$QD,3\,KO-9ZKAA9Z(H ;(^HU.Y'!-^;!Y#
M<HK&9SI!5/I#G1 JSFMP2,HH4C !B[@06=L8+75"12%=\48O^/B9NAEF-&"'
M#CUE$*4 UDX3XV7H&K@#)AAA<OF[@&8ASM4_L7,'V#4Y9+ND^KXO^]6<&W<0
M\/:T?YG7+:S/I+S&\5>VDBX1-^PV^76U?3SL6%MQL2[XNA#B(&HI*LGK]\GU
MA]]=V 5CC_8?&]\$VP9^W47[!5!+ P04    " ")@2M/F5R<(Q &  "<)P
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M_VTP",\.&C'._MAL]3T[MU9.[Z5HM8*XEM\63&XL6&1\K4,ZX\2KYPLWI?(
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M7H(PK8>_R43]-<#JUV5?4$L#!!0    ( (F!*T\+C]@#(0$  %<$   3
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M+G)E;'-02P$"% ,4    " ")@2M/)^B'#H(   "Q    $
M@ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (F!*T_+W[9Y[@
M "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( (F!*T^97)PC$ 8  )PG   3              "  ;8"  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ B8$K3R6_JWJ8 @  DPL  !@
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9>&UL4$L%!@     *  H @ (   ,4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>cry-20190911x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cry-20190911.xsd" xlink:type="simple"/>
    <context id="Duration_9_11_2019_To_9_11_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
        </entity>
        <period>
            <startDate>2019-09-11</startDate>
            <endDate>2019-09-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-1">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-9">0000784199</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-4">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-3">2019-09-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-13">CRYOLIFE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-12">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-11">1-13165</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-14">59-2417093</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-5">1655 Roberts Boulevard, N.W.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-6">Kennesaw</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-8">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-7">30144</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-2">770</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-15">419-3355</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-18">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-21">CRY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-19">NYSE</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-22">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-20">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_9_11_2019_To_9_11_2019"
      id="ct-nonNumeric-10">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cry-20190911x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cryolife.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="cry-20190911x8k.htm">cry-20190911x8k.htm</File>
    <File>cry-20190911.xsd</File>
    <File>cry-20190911_lab.xml</File>
    <File>cry-20190911_pre.xml</File>
    <File>cry-20190911xex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6607630096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 11, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cry_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 11,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000784199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CRYOLIFE, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-13165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">59-2417093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1655 Roberts Boulevard, N.W.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Kennesaw<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">419-3355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cry_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cry_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cry-20190911x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cry-20190911x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cry-20190911_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cry-20190911_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cry-20190911.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cry",
   "nsuri": "http://www.cryolife.com/20190911",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cry-20190911x8k.htm",
      "contextRef": "Duration_9_11_2019_To_9_11_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document And Entity Information",
     "role": "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cry-20190911x8k.htm",
      "contextRef": "Duration_9_11_2019_To_9_11_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "cry_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Document and Entity Information",
        "label": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.cryolife.com/20190911",
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cryolife.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000784199-19-000151-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000784199-19-000151-xbrl.zip
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MN6-M NJ#1Z/4Y9-'NR'KHT<9 D4,E$&2FO+SAEV.'\?%?V%=_@=02P,$%
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M\NI3LOQ.,EM.([=$:.0]ME:VY[16\H:D_?*'A  ?6E<KL);N/[F4%N)@L>+
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M=6)KLFGMD=;9%:DW:A5X<5JV1FX8MQ"$R]RHTIIY_]F)9I9PN0UDZ-U^ N4
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MIKGO)]H'J$]9!RX"R5X*[VN="Q:7YQ5KT0OO8AG[:'')2'R7XWS!628H&5/
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MG%L GFC"EEBH0L&^/S_!_['T1UID[J]=%<=J./]WJX6G?T[E7JV.<#A<X%[
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M'Y_BW(-X&)S^/U!+ 0(4 Q0    ( (F!*T\Z=-M_( ,  $(*   0
M      "  0    !C<GDM,C Q.3 Y,3$N>'-D4$L! A0#%     @ B8$K3SY2
MC$W*!0  5C<  !0              ( !3@,  &-R>2TR,#$Y,#DQ,5]L86(N
M>&UL4$L! A0#%     @ B8$K3Q4(+W!N!   #2H  !0              ( !
M2@D  &-R>2TR,#$Y,#DQ,5]P<F4N>&UL4$L! A0#%     @ B8$K3Z&6-'EI
M&@  /#P! !,              ( !Z@T  &-R>2TR,#$Y,#DQ,7@X:RYH=&U0
M2P$"% ,4    " ")@2M/3"J=UTH:   OL   %P              @ &$*
M8W)Y+3(P,3DP.3$Q>&5X.3E?,2YH=&U02P4&      4 !0!( 0   T,

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
